Zenas BioPharma Inc. (ZBIO)
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 26.24 0.00%
ZBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.71B
- EPS (TTM)
- -$9.63
- Dividend yield
- None
- 52-week range
- 13.50 – 44.60
- Day range
- 25.51 – 27.98
- Volume / Avg
- 557.49K / 735.12K
- Beta
- —
- Shares outstanding
- 65.18M
52-week range
ZBIO stock today
Shares of Zenas BioPharma (ZBIO) finished lower on Oct 8 at $26.24, a drop of 6.88% or $1.94 per share, versus the S&P 500's 0.47% decline. At this level, ZBIO sits in the middle of its 52-week range of $13.50 to $44.60: 41.2% below the high, set on Dec 24, 2025 and 94.4% above the low. ZBIO is down 22.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 35.2%.
Zenas BioPharma has posted a net loss over the last twelve months (EPS of -$9.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Zenas BioPharma
Company profileZenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Leon Oliver Moulder Jr., M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 167
- IPO year
- 2024
- Website
- zenasbio.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$47.88+82.47%
- Strong buy 0
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Zenas BioPharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GPCRStructure Therapeutics Inc. ADR | 25.67 | -3.79% | $1.83B | vs ZBIO |
| TRVITrevi Therapeutics Inc. | 12.83 | -2.40% | $1.83B | vs ZBIO |
| XNCRXencor Inc. | 24.50 | +0.99% | $1.82B | vs ZBIO |
| XERSXeris Biopharma Holdings Inc. | 10.19 | +0.79% | $1.86B | vs ZBIO |
| ZYMEZymeworks Inc. | 25.26 | -4.79% | $1.81B | vs ZBIO |
| URGNUroGen Pharma Ltd. | 36.98 | -9.14% | $1.81B | vs ZBIO |
| BHVNBiohaven Ltd. | 11.93 | +0.42% | $1.80B | vs ZBIO |
| GENBGenerate Biomedicines Inc. | 13.99 | +3.10% | $1.80B | vs ZBIO |
Indexes, lists and sector
Zenas BioPharma stock FAQ
What is Zenas BioPharma's stock price today?
ZBIO last traded at $26.24 as of Oct 8, 4:00 PM EDT, down 6.88% on the day. Prices are delayed at least 15 minutes.
Who is Zenas BioPharma's CEO?
Mr. Leon Oliver Moulder Jr., M.B.A. is the chief executive officer of Zenas BioPharma Inc., which has about 167 employees.
What is the ZBIO 52-week high?
The 52-week high for ZBIO is $44.60 and the 52-week low is $13.50. The stock is currently 41.2% below its high.